AstraZeneca Plc’s profit rose more than analysts anticipated last quarter, buoyed by strong sales of its blockbuster cancer and diabetes drugs.

The company’s impressive financial performance exceeded market expectations, reflecting robust demand for its key medications. This growth highlights AstraZeneca’s continued success in the pharmaceutical sector, driven by innovative treatments that address critical health conditions.
https://www.bloomberg.com/news/articles/2025-11-06/astrazeneca-profit-beats-estimates-on-cancer-diabetes-drugs